Sino Biopharmaceutical Limited has announced that its jointly developed drug, LM-108, a CCR8 monoclonal antibody, has been included in the Breakthrough Therapy Designation (BTD) process by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. This development, in collaboration with LaNova Medicines Limited, aims to treat CCR8-positive advanced gastric/gastroesophageal junction adenocarcinoma in patients who have not responded to first-line standard therapy. This inclusion in the BTD process marks a significant step forward in the development of next-generation immunotherapy options for tumors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。